Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (160,199)	$ (145,941)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	14,364	7,834
Noncash lease expense	5,423	5,259
Share-based compensation expense	41,183	31,376
Intangible assets amortization	1,270	1,270
Investment amortization	1,825	5,956
Research and development inventory reserve	2,638
Interest expense	653
Other	(20)	(9)
Changes in operating assets and liabilities
Accounts receivable, net	(9,139)	(7,075)
Inventory	(2,212)	(4,168)
Prepaid expenses and other current assets	601	(2,239)
Accounts payable and accrued liabilities	(3,419)	5,518
Operating lease right-of-use assets and liabilities	(3,041)	9,935
Deferred revenue	(44,018)	(46,345)
Other	165	(272)
Net cash used in operating activities	(153,926)	(138,901)
Investing activities
Purchases of property and equipment	(13,807)	(52,501)
Purchases of marketable securities	(113,744)	(238,001)
Proceeds from maturities of marketable securities	228,000	404,500
Net cash provided by investing activities	100,449	113,998
Financing activities
Proceeds from exercise of stock options	7,568	23,439
Proceeds from revenue interest purchase agreement, net of issuance costs	124,691
Proceeds from initial capital contributions for Digital Biotechnologies, Inc.		429
Net cash provided by financing activities	132,259	23,868
Net increase (decrease) in cash, cash equivalents and restricted cash	78,782	(1,035)
Cash, cash equivalents and restricted cash at beginning of year	141,203	125,574
Cash, cash equivalents and restricted cash at end of period	219,985	124,539
Noncash investing and financing activities
Purchases of equipment included in accounts payable and accrued liabilities	2,619	$ 8,133
Revenue interest purchase agreement issuance costs included in accounts payable and accrued liabilities	$ 316